Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Receivables: 2011-2025

Historic Receivables for Amicus Therapeutics (FOLD) over the last 13 years, with Sep 2025 value amounting to $113.8 million.

  • Amicus Therapeutics' Receivables rose 16.07% to $113.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $409.1 million, marking a year-over-year increase of 17.79%. This contributed to the annual value of $101.1 million for FY2024, which is 15.37% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Receivables stood at $113.8 million, which was up 7.55% from $105.8 million recorded in Q2 2025.
  • Amicus Therapeutics' Receivables' 5-year high stood at $113.8 million during Q3 2025, with a 5-year trough of $44.9 million in Q1 2021.
  • Moreover, its 3-year median value for Receivables was $87.6 million (2023), whereas its average is $87.4 million.
  • Data for Amicus Therapeutics' Receivables shows a peak YoY soared of 40.20% (in 2023) over the last 5 years.
  • Over the past 5 years, Amicus Therapeutics' Receivables (Quarterly) stood at $52.7 million in 2021, then increased by 25.68% to $66.2 million in 2022, then skyrocketed by 32.38% to $87.6 million in 2023, then climbed by 15.37% to $101.1 million in 2024, then grew by 16.07% to $113.8 million in 2025.
  • Its Receivables was $113.8 million in Q3 2025, compared to $105.8 million in Q2 2025 and $88.3 million in Q1 2025.